Connect with us

Temasek Invests in Yichang Hec Changjiang Pharmaceutical

Published

on

Singapore’s Temasek Holdings has invested in a Chinese pharmaceutical company that manufactures an anti-flu product, among other drugs. Through a series of subsidiaries, Bartley Investments Pte. Ltd., a sovereign wealth enterprise (SWE) of Temasek Holdings, purchased 15.1 million H shares in Yichang Hec Changjiang Pharmaceutical Company Limited. This transaction was recorded on April 27, 2017. The average price per share was HK$ 16.30.

Yichang Hec Changjiang Pharmaceutical was formed in August 2001. The company focuses on the development, manufacturing and sale of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases and cardiovascular diseases. According to the company, Kewei (oseltamivir phosphate) is the #1 selling influenza drug in China from 2013 to 2016.

TaiGen Deal

On March 27, 2017, Taiwan-based TaiGen Biopharmaceuticals Co. (Beijing), Ltd., a unit of TaiGen Biotechnology, sold its 9% equity stake in Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. to Yichang Hec Changjiang Pharmaceutical. Dongguan HEC TaiGen Biopharmaceuticals is a joint venture between Yichang Hec Changjiang Pharmaceutical and TaiGen Biopharmaceuticals Co. (Beijing), Ltd.

Mauritius Aims to Sell Citizenship and Passports to Bolster National Wealth Fund

Published

on

The island country of Mauritius plans to offer foreigners a chance to obtain country citizenship in exchange for a non-refundable contribution of US$ 1 million to the national sovereign wealth fund. [ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Continue Reading

CapitaLand Aims to be a Real Estate Funding Machine

Published

on

CapitaLand Investment Management, a real estate investment management arm of Singapore-based CapitaLand, hired Caleb Shen as managing director for fund management. CapitaLand is keen on growing its real estate fund management business. [ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Continue Reading

Treasurer Perrottet Reveals the NSW Generations Fund

Published

on

New South Wales wants its own Future Fund.

[ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Continue Reading

Popular

© 2008-2018 Sovereign Wealth Fund Institute. All Rights Reserved. Sovereign Wealth Fund Institute ® and SWFI® are registered trademarks of the Sovereign Wealth Fund Institute. Other third-party content, logos and trademarks are owned by their perspective entities and used for informational purposes only. No affiliation or endorsement, express or implied, is provided by their use. All material subject to strictly enforced copyright laws. Registration on or use of this site constitutes acceptance of our terms of use agreement which includes our privacy policy. Sovereign Wealth Fund Institute (SWFI) is a global organization designed to study sovereign wealth funds, pensions, endowments, superannuation funds, family offices, central banks and other long-term institutional investors in the areas of investing, asset allocation, risk, governance, economics, policy, trade and other relevant issues. SWFI facilitates sovereign fund, pension, endowment, superannuation fund and central bank events around the world. SWFI is a minority-owned organization.